Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
70 hedge funds and large institutions have $338M invested in Stemline Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
84% more capital invested
Capital invested by funds: $184M → $338M (+$154M)
25% more funds holding
Funds holding: 56 → 70 (+14)
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$10.1M |
| 2 |
Goldman Sachs
New York
|
+$5.71M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.11M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$5.1M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$16.4M |
| 2 |
Neuberger Berman Group
New York
|
-$5.43M |
| 3 |
VAM
Visium Asset Management
New York
|
-$4.89M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.25M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.48M |
STML Hedge Fund Activity: Q3 2013 in Review
70 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2013, worth a combined $338M — up 84% from $184M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STML positions and 5 closed out — a net gain of 15 holders — while 22 added to existing stakes and 21 trimmed.
The largest buyer was SAC Capital Advisors, adding an estimated $10.1M. The largest seller was Perceptive Advisors, cutting an estimated $16.4M.
- 70 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2013, up from 56 in Q2 2013.
- Funds reported $338M of Stemline Therapeutics, Inc. stock for Q3 2013, up 84% quarter-over-quarter.
- 20 funds opened new Stemline Therapeutics, Inc. positions in Q3 2013 and 5 closed out, a net change of +15 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2013 was SAC Capital Advisors, an estimated $10.1M added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2013 was Perceptive Advisors, an estimated $16.4M sold.
Based on aggregated 13F filings for Q3 2013.